overactive blaadder

Updated: November 25, 2022

Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

mirabegron

Monotherapy:

25 - 50

Tablet

Orally 

every day

Combined with muscarinic agonist
25mg orally everyday combined with 5mg every day solifenacin succinate, up to 50mg orally every day after 4-8 weeks

flavoxate

100 - 200

Tablet

Orally 

every 6-8 hours

100-200mg orally every 6-8 hours

vibegron

75mg orally every day

Dose Adjustments

Hepatic Impairment
Mild to moderate (Child-Pugh A and B): No dosage modification is required
Extreme (Child-Pugh C): Not advised

Renal Impairment
Mild-to-severe (eGFR 15 to <90 mL/min/1.73 m2): No dose change is needed.
End-stage renal failure without hemodialysis (eGFR <15 mL/min/1.73 m2): Not advised

propiverine

Take an initial dose of 30 mg one time a day and it may raise up to 45 mg one time a day

fesoterodine

4 mg orally every day; may increase up to 8 mg orally a day based upon tolerability and response 

Dosage Modifications 
Renal impairment 
Mild-to-moderate: Not required 
CrCl <30 mL/min: do not exceed 4 mg orally per day 

propiverine

for Children and Adolescents:
Take a daily dose of 0.8 mg/kg orally in 2 divided doses
Dose of 5 mg two twice a day for 12 to 16 kg
Dose of 5 mg in the morning and 10 mg in the evening for 17 to 22 kg
Dose of 10 mg twice a day for 23 to 28 kg
Dose of 10 mg in the morning and 15 mg in the evening for 29 to 34 kg
Dose of 15 mg twice a day for ≥35 kg

Future Trends